CERRITOS, Calif, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (TOI) announced today that it has started operations of its first pharmacy in California after receiving approval from the California State Board of Pharmacy. This new service allows TOI to fill not only critical specialty medications and chemotherapeutics for MediCal patients, but also to provide medication fill capabilities to other patient populations. Located in the Los Angeles area, this new pharmacy location comes in addition to the multiple integrated specialty medication dispensaries that TOI already uses to manage oral and injectable medications.
“We are ecstatic that we finally have the opportunity to significantly expand our oral drug business with this new pharmacy location,” shared Chief Executive Officer, Dr. Daniel Virnich. “We are seeking to address the cancer care costs of hundreds of thousands of MediCal patients that we were unable to serve through our dispensaries. Now, we expect to be able to fill their medications more quickly and conveniently.”
“TOI has proudly lowered out-of-pocket costs for patients that fill through our medically integrated dispensaries. We expect this to continue as we begin operations at our first pharmacy location,” commented Jessica Yankus, TOI’s National Vice President of Pharmacy. “This is an incredible service for both our patients and payor partners, so we anticipate similar opportunities to emerge in other states where we deliver care.”
About TOI
Founded in 2007, The Oncology Institute, Inc. (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.73 |
Daily Change: | 0.06 1.63 |
Daily Volume: | 1,570,890 |
Market Cap: | US$342.820M |
June 30, 2025 May 14, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load